{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:27:50Z","timestamp":1793363270133,"version":"4.5.0"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T00:00:00Z","timestamp":1664236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genet."],"abstract":"<jats:p>The RASopathies are a group of genetic conditions resulting from mutations within the RAS\/mitogen-activated protein kinase (RAS-MAPK) pathway. Lymphatic abnormalities are commonly associated with these conditions, however central conducting lymphatic abnormalities (CCLA) have only recently been described. CCLAs may be progressive and can result in devastating systemic sequelae, such as recurrent chylothoraces, chylopericardium and chylous ascites which can cause significant morbidity and even mortality. Improvements in imaging modalities of the central lymphatics have enhanced our understanding of these complex abnormalities. Management is challenging and have mainly consisted of diuretics and invasive mechanical drainages. We describe two adult males with Noonan syndrome with a severe and progressive CCLA. In one patient we report the therapeutic role of targeted molecular therapy with the MEK inhibitor \u2018Trametinib\u2019, which has resulted in dramatic, and sustained, clinical improvement. The successful use of MEK inhibition highlights the importance of understanding the molecular cause of lymphatic abnormalities and utilising targeted therapies to improve quality of life and potentially life expectancy.<\/jats:p>","DOI":"10.3389\/fgene.2022.1001105","type":"journal-article","created":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T04:49:49Z","timestamp":1664254189000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":30,"title":["Case Report: Progressive central conducting lymphatic abnormalities in the RASopathies. Two case reports, including successful treatment by MEK inhibition"],"prefix":"10.3389","volume":"13","author":[{"given":"Kristiana","family":"Gordon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malou","family":"Van Zanten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Pearce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxim","family":"Itkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Madden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Ratnam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.","family":"Mortimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rani","family":"Nagaraja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1016\/j.jacc.2019.01.066","article-title":"Hypertrophic cardiomyopathy in noonan syndrome treated by MEK-inhibition","volume":"773","author":"Andelfinger","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"4418","DOI":"10.1038\/onc.2013.581","article-title":"Oncogenic RIT1 mutations in lung adenocarcinoma","volume":"33","author":"Berger","year":"2014","journal-title":"Oncogene"},{"key":"B3","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s00247-018-04337-6","article-title":"Imaging of central lymphatic abnormalities in noonan syndrome","volume":"49","author":"Biko","year":"2019","journal-title":"Pediatr. Radiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1024\/0301-1526\/a000414","article-title":"Combined and complex vascular malformations","volume":"44","author":"Clemens","year":"2015","journal-title":"Vasa."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e20200167","DOI":"10.1542\/peds.2020-0167","article-title":"Severe lymphatic disorder resolved with MEK inhibition in a patient with noonan syndrome and SOS1 mutation","volume":"146","author":"Dori","year":"2020","journal-title":"Pediatrics"},{"key":"B6","doi-asserted-by":"publisher","first-page":"16395","DOI":"10.1073\/pnas.1418126111","article-title":"K-RasV14I recapitulates Noonan syndrome in mice","volume":"111","author":"Hernandez-Porras","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B7","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/ejhg.2015.175","article-title":"The lymphatic phenotype in noonan and cardiofaciocutaneous syndrome","volume":"23","author":"Joyce","year":"2015","journal-title":"Eur. J. Hum. Genet."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e1109","DOI":"10.1634\/theoncologist.2020-0069","article-title":"The use of MEK inhibitors in neurofibromatosis type 1-associated tumors and management of toxicities","volume":"25","author":"Klesse","year":"2020","journal-title":"Oncologist"},{"key":"B9","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s005350170142","article-title":"Primary intestinal lymphangiectasia successfully treated with octreotide","volume":"36","author":"Kuroiwa","year":"2001","journal-title":"J. Gastroenterol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/s41591-019-0479-2","article-title":"ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor","volume":"25","author":"Li","year":"2019","journal-title":"Nat. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.1093\/hmg\/ddy218","article-title":"Pathogenic variant in EPHB4 results in central conducting lymphatic anomaly","volume":"27","author":"Li","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e20152694","DOI":"10.1542\/peds.2015-2694","article-title":"A case of a central conducting lymphatic anomaly responsive to sirolimus","volume":"137","author":"McCormick","year":"2016","journal-title":"Pediatrics"},{"key":"B13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/ajmg.1320240115","article-title":"On congenital lymphedema","volume":"24","author":"Opitz","year":"1986","journal-title":"Am. J. Med. Genet."},{"key":"B14","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1146\/annurev-genom-091212-153523","article-title":"The RASopathies","volume":"14","author":"Rauen","year":"2013","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"key":"B15","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S0140-6736(12)61023-X","article-title":"Noonan syndrome","volume":"381","author":"Roberts","year":"2013","journal-title":"Lancet"},{"key":"B16","first-page":"1993","article-title":"Noonan syndrome","volume-title":"GeneReviews\u00ae","author":"Roberts","year":"2001"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.1002\/ajmg.a.35639","article-title":"Medical complications, clinical findings and educational outcomes in adults with Noonan syndrome","author":"Smpokou","year":"2012","journal-title":"Am. J. Med. Genet. A"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1159\/000276766","article-title":"Noonan syndrome: Clinical aspects and molecular pathogenesis","volume":"1","author":"Tartaglia","year":"2010","journal-title":"Mol. Syndromol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1053\/j.sempedsurg.2014.07.006","article-title":"Complex lymphatic anomalies","volume":"23","author":"Trenor","year":"2014","journal-title":"Semin. Pediatr. Surg."},{"key":"B20","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1002\/ajmg.1320270412","article-title":"Lymphedema in noonan syndrome: Clues to pathogenesis and prenatal diagnosis and review of the literature","volume":"27","author":"Witt","year":"1987","journal-title":"Am. J. Med. Genet."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1172\/JCI44929","article-title":"MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of noonan syndrome associated with the Raf1(L613V) mutation","volume":"121","author":"Wu","year":"2011","journal-title":"J. Clin. Invest."}],"container-title":["Frontiers in Genetics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2022.1001105\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T09:24:05Z","timestamp":1665566645000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2022.1001105\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,27]]},"references-count":21,"alternative-id":["10.3389\/fgene.2022.1001105"],"URL":"https:\/\/doi.org\/10.3389\/fgene.2022.1001105","relation":{},"ISSN":["1664-8021"],"issn-type":[{"value":"1664-8021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,27]]},"article-number":"1001105"}}